Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

  1. Garassino, M.C.
  2. Cho, B.-C.
  3. Kim, J.-H.
  4. Mazières, J.
  5. Vansteenkiste, J.
  6. Lena, H.
  7. Jaime, J.C.
  8. Gray, J.E.
  9. Powderly, J.
  10. Chouaid, C.
  11. Bidoli, P.
  12. Wheatley-Price, P.
  13. Park, K.
  14. Soo, R.A.
  15. Poole, L.
  16. Wadsworth, C.
  17. Dennis, P.A.
  18. Rizvi, N.A.
Revista:
Lung Cancer

ISSN: 1872-8332,  0169-5002

Any de publicació: 2020

Volum: 147

Pàgines: 137-142

Tipus: Article

DOI: 10.1016/J.LUNGCAN.2020.06.032 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus